The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.

Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

See which services passed our rigorous vetting process. Share on Pinterest Mounjaro (tirzepatide) is an injectable medication that’s approved for diabetes by the Food and Drug Administration (FDA).

Mounjaro is a prescription glucagon-like peptide-1 (GLP-1) drug with the active ingredient tirzepatide. Doctors prescribe it for the treatment of type 2 diabetes, but they may also prescribe it ...

If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. SAN ...